InMed Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for InMed Pharmaceuticals.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.7%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

Sep 26

InMed Pharma announces $6M private placement

Sep 09

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

Jul 25

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

Jul 13

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

Jul 02

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

Jan 08

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak InMed Pharmaceuticals yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:INM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	5	-8	-7	-7	N/A
3/31/2024	6	-6	-7	-7	N/A
12/31/2023	5	-6	-7	-6	N/A
9/30/2023	5	-7	-7	-7	N/A
6/30/2023	4	-8	-7	-7	N/A
3/31/2023	2	-15	-11	-11	N/A
12/31/2022	2	-17	-14	-14	N/A
9/30/2022	1	-19	-15	-15	N/A
6/30/2022	1	-19	-16	-16	N/A
3/31/2022	1	-14	-14	-14	N/A
12/31/2021	0	-14	-13	-13	N/A
9/30/2021	N/A	-12	-11	-11	N/A
6/30/2021	N/A	-10	-10	-10	N/A
3/31/2021	N/A	-9	-9	-9	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	-8	-6	-6	N/A
6/30/2020	N/A	-9	-7	-7	N/A
3/31/2020	N/A	-10	-8	-8	N/A
12/31/2019	N/A	-11	-9	-8	N/A
9/30/2019	N/A	-10	-8	-8	N/A
6/30/2019	N/A	-10	-7	-7	N/A
3/31/2019	N/A	-9	-6	-6	N/A
12/31/2018	N/A	-8	-4	-4	N/A
9/30/2018	N/A	-7	-4	-4	N/A
6/30/2018	N/A	-6	-4	-4	N/A
3/31/2018	N/A	-6	N/A	-3	N/A
12/31/2017	N/A	-5	N/A	-3	N/A
9/30/2017	N/A	-5	N/A	-3	N/A
6/30/2017	N/A	-3	N/A	-2	N/A
3/31/2017	N/A	-2	N/A	-2	N/A
12/31/2016	N/A	-2	N/A	-1	N/A
9/30/2016	N/A	-2	N/A	0	N/A
6/30/2016	N/A	-2	N/A	0	N/A
3/31/2016	N/A	-3	N/A	-1	N/A
12/31/2015	N/A	-3	N/A	-2	N/A
9/30/2015	N/A	-3	N/A	-2	N/A
6/30/2015	N/A	-3	N/A	-2	N/A
3/31/2015	N/A	-3	N/A	-1	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	0	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if INM's forecast earnings growth is above the savings rate (2.5%).

Kazançlar ve Piyasa: Insufficient data to determine if INM's earnings are forecast to grow faster than the US market

Yüksek Büyüme Kazançları: Insufficient data to determine if INM's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if INM's revenue is forecast to grow faster than the US market.

Yüksek Büyüme Geliri: Insufficient data to determine if INM's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if INM's Return on Equity is forecast to be high in 3 years time

InMed Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

High number of new and inexperienced directors

InMed Pharmaceuticals Inc. Announces the Appointment of Dr. Barry Greenberg to Its Scientific Advisory Board

New major risk - Financial position

Full year 2024 earnings released: US$1.01 loss per share (vs US$3.25 loss in FY 2023)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 18, 2024

InMed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $1.03019 million.

New major risk - Financial position

Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.60 loss in 3Q 2023)

InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.91 loss in 2Q 2023)

InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024

Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089

InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding

Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901

InMed Pharmaceuticals Inc. announced that it expects to receive CAD 2.500001 million in funding

InMed Pharmaceuticals Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$3.25 loss per share (vs US$33.17 loss in FY 2022)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 19, 2023

InMed Pharmaceuticals Inc. announced delayed 10-Q filing

InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer

InMed Pharmaceuticals Inc. announced that it has received CAD 6.000011 million in funding

Inmed Pharmaceuticals Inc. Announces Promotion of Sarah Li to Controller and Principal Accounting Officer

Inmed Pharmaceuticals Inc. Provides Update on Management Changes

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada Alliance Grant Funding

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 15, 2022

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

InMed Pharmaceuticals Inc. to Report Fiscal Year 2022 Results on Sep 23, 2022

InMed Pharmaceuticals Inc. announced that it has received $6.000007 million in funding

InMed Pharmaceuticals Inc. announced that it expects to receive $6.000007 million in funding

InMed Pharma announces $6M private placement

InMed Pharmaceuticals Inc. Appoints Nicole Lemerond to Its Board of Directors

InMed Pharmaceuticals Inc. Provides an Update on Its Phase 2 Clinical Trial

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

InMed Pharmaceuticals Inc. Announces Michael Woudenberg Has Been Appointed Chief Operating Officer

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

InMed Pharmaceuticals Inc. Receives Written Notice from the Listing Qualifications Department Staff of the Nasdaq Capital Market

InMed Pharmaceuticals Inc. Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

InMed Pharmaceuticals Inc. announced that it has received $1.499999 million in funding

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $3.500002 million.

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $4.25 million.

Inmed Pharmaceuticals Inc. Announces Appointment of Bryan Baldasare to Its Board of Directors Effective May 13, 2022

InMed Pharmaceuticals Inc. Cannabidivarin, Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. Announces Board Changes

InMed Pharmaceuticals Inc. to Report Q2, 2022 Results on Feb 15, 2022

InMed Launches Cannabicitran (CBT), Expanding Its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. announced that it has received $12 million in funding

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

InMed Pharmaceuticals Inc. (NasdaqCM:INM) entered into a nonbinding letter of intent to acquire BayMedica Inc. for $4.7 million.

Inmed Pharmaceuticals Increases Cannabinoid Yield to 5 G/L with IntegraSyn in Advance of Commercial Scale Production

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Achieves 2G/L Cannabinoid Yield with Integrasyn

InMed Pharmaceuticals Inc. announced that it has received $4.4625 million in funding

New 90-day high: US$5.35

InMed Pharmaceuticals Inc. announced that it expects to receive $4.499998 million in funding

InMed Pharmaceuticals Inc. Announces Top-Line Results from Its 755-102-HV Phase 1 clinical trial

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin